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The frequency of micronuclei (MN) in peripheral blood
lymphocytes (PBL) is extensively used as a biomarker of
chromosomal damage and genome stability in human
populations. Much theoretical evidence has been accumu-
lated supporting the causal role of MN induction in cancer
development, although prospective cohort studies are
needed to validate MN as a cancer risk biomarker. A
total of 6718 subjects from of 10 countries, screened in
20 laboratories for MN frequency between 1980 and 2002
in ad hoc studies or routine cytogenetic surveillance, were
selected from the database of the HUman MicroNucleus
(HUMN) international collaborative project and followed
up for cancer incidence or mortality. To standardize for
the inter-laboratory variability subjects were classified
according to the percentiles of MN distribution within
each laboratory as low, medium or high frequency. A
significant increase of all cancers incidence was found for
subjects in the groups with medium (RR ¼ 1.84; 95% CI:
1.28–2.66) and high MN frequency (RR ¼ 1.53; 1.04–2.25).
The same groups also showed a decreased cancer-free
survival, i.e. P ¼ 0.001 and P ¼ 0.025, respectively. This
association was present in all national cohorts and for all
major cancer sites, especially urogenital (RR ¼ 2.80; 1.17–
6.73) and gastro-intestinal cancers (RR ¼ 1.74; 1.01–4.71).
The results from the present study provide preliminary
evidence that MN frequency in PBL is a predictive
biomarker of cancer risk within a population of healthy
subjects. The current wide-spread use of the MN assay
provides a valuable opportunity to apply this assay in
the planning and validation of cancer surveillance and
prevention programs.
Introduction
Measurement of micronucleus (MN) frequency in peripheral
blood lymphocytes (PBL) is extensively used in molecular
epidemiology and cytogenetics to evaluate the presence and
the extent of chromosomal damage in human populations
exposed to genotoxic agents or bearing a susceptible genetic
profile (1). This assay has been also successfully applied to
identify dietary and genetic factors that have a significant
impact on genome stability (2). The high reliability and low
cost of the MN technique, has contributed to the worldwide
success and adoption of this biomarker for in vitro and in vivo
studies of genome damage (3).
MN originate from chromosome fragments or whole
chromosomes that are not included in the main daughter
nuclei during nuclear division (Figure 1). The formation of
MN in dividing cells is the result of chromosome breakage
due to unrepaired or mis-repaired DNA lesions, or chromo-
some malsegregation due to mitotic malfunction. These
events may be induced by oxidative stress, exposure to clasto-
gens or aneugens, genetic defects in cell cycle checkpoint
and/or DNA repair genes, as well as deficiencies in nutrients
required as co-factors in DNA metabolism and chromosome
segregation machinery (2,4–8). All these events can cause
the formation of MN through chromosomal rearrangements,
altered gene expression or aneuploidy, effects associated
Abbreviations: CA, chromosomal aberrations; HUMN, HUman Micro-
Nucleus project; MN, micronucleus; PBL, peripheral blood lymphocytes.
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with the chromosome instability phenotype often seen in
cancer (5,9–11).
The presence of an association between MN induction and
cancer development is supported by a number of observa-
tions. The most substantiated include: (i) the high frequency
of this biomarker in untreated cancer patients and in subjects
affected by cancer-prone congenital diseases, e.g. Bloom
syndrome or ataxia telangiectasia (1,9); (ii) the presence of
elevated MN frequencies in oral mucosa, used as a surrogate
biomarker of cancer in clinical chemoprevention trials (12);
(iii) the correlation existing between genotoxic MN-inducing
agents and carcinogenicity, e.g. ionizing and ultraviolet
radiation (13,14); and (iv) the inverse correlation between
MN frequency and the blood concentration and/or dietary
intake of certain micronutrients associated with reduced
cancer risk, such as folate, calcium, vitamin E and nicotinic
acid (8). Further evidence—based on the mechanistic and
experimental correlation existing between chromosomal
aberrations (CA) and MN (1,9)—comes from the results of
recent cohort studies, which in most cases demonstrated that
the frequency of CA in PBL of healthy subjects is a predictor
of cancer risk (15–19). The possible association of lympho-
cyte MN frequency with cancer risk has earlier been
examined in Swedish and Italian cohorts (15,16), although
no conclusions could be drawn from those studies because of
the young age of the cohorts and the small number of events
(18 cancer cases and 9 cancer deaths).
To test the hypothesis that PBL MN are predictive of
increased cancer risk, we assembled a large international
cohort of subjects whose lymphocytes had been screened for
MN frequency between 1980 and 2002 and who were free
of cancer at the time of testing. The study was conducted
within the framework of the HUman MicroNucleus project
(HUMN), an international collaborative project, which
allowed gathering of data on 6718 individuals studied in
20 cytogenetics laboratories from 10 countries (1).
Subjects and methods
The international collaborative HUMN project was developed to improve
knowledge of the biology and relevance of MN induction and its application
to human population studies (1). Details about this initiative and the list of
publications produced under the HUMN project can be found on the project
website, www.HUMN.org. The study was also part of the Cytogenetic
Biomarkers and Human Cancer Risk project (CancerRiskBiomarkers),
a European collaborative research project funded by the European Union.
About 50 laboratories actively involved in the HUMN project or included
in the mailing list were invited to contribute their databases to the cohort
study, assuming that personal identification was available for all subjects and
a link with local or national cancer registry was possible. An arbitrarily
chosen minimum size of 100 subjects analysed in the same laboratory (even
in different studies) was required to be eligibile for inclusion in the cohort. A
detailed description of the protocol used for measurement of MN frequency
in PBL was collected from each laboratory submitting a database and
evaluated by the HUMN steering committee for compliance to acceptable
standard methodology (10). Altogether, 20 laboratories from 10 countries,
that were measuring MN frequency in human populations as a routine
procedure, submitted databases that fulfilled the inclusion criteria, and all
were included in the study.
Only individual MN frequencies based on the scoring of at least
1000 interphase cells were considered for statistical analysis. The large
majority of laboratories adopted the cytokinesis-block assay (20), scoring
MN frequency in binucleated lymphocytes cells. The dataset from Sweden
was produced using a different protocol, and MN were scored in mono-
nuclear lymphocytes (21), but this difference did not influence the statistical
analysis of data.
The subjects were originally selected by the testing laboratories
for cytogenetic ad hoc studies, or routine biological dosimetry because of
their exposures to mutagens or carcinogens, or as unexposed referents. The
original cytogenetic studies were performed between 1980 and 2002, and
most of them have been published in the peer-reviewed scientific literature.
The most commonly studied exposures were to ionizing radiation (1355
subjects), pesticides (318 subjects), polycyclic aromatic hydrocarbons (264
subjects) organic solvents (292 subjects) and cytostatic drugs (182 subjects).
The cohorts investigated in this study were different from those that were
previously studied to determine the relationship between CA in PBL and
cancer risk (15–19).
All subjects included in the HUMN cohort had a valid personal
identification code, were at least 15 years old, and free of cancer at the
time of cytogenetic testing. The study protocol was approved by the ethics
committee of the coordinating center at the National Cancer Research
Institute of Genoa, Italy. The list of national cohorts with selected
characteristics is reported in Table I. Overall, 6718 subjects, accounting for
a total of 62 980 person-years, were studied.
Seventy subjects included in the cohort were tested more than once.
Repeated measures showed a good degree of internal agreement (r ¼ 0.68;
P < 0.01), however only the result of the first test was considered for the
statistical analysis. We used the ‘non-concurrent’ cohort study approach
which is the most suitable epidemiologic design to evaluate long-term effects
of early genetic damage, when the biomarker may be affected by the disease,
i.e. reverse causality bias (22). The follow-up period began with the date
of MN testing and ended with death, cancer diagnosis, emigration,
85th birthday or end of follow-up (1999–2004, depending on the country),
whichever occurred first. The median duration of follow-up was 8.0 years.
Information on cancer incidence was obtained by linking the cohorts with
national or regional cancer registries. In Poland, an active system of follow-
up was set up via contacts with local cancer registries, municipalities of
residence, employers, pension funds and general practitioners. In Italy and
Belgium, mortality data were available and information on causes of death
was collected via postal follow-up from the Municipality of residence. It was
possible to follow the incidence for a subset of 245 Italian subjects (7 cancer
cases; 1459 person-years), and these data were included in the statistics of
Fig. 1. (A) Schematic diagram showing the origin of MN from either a lagging chromosome fragment or a whole chromosome. (B) A photomicrograph of
a mitogen-stimulated, cytokinesis-blocked lymphocyte containing one MN.
626
S.Bonassi et al.
Downloaded from https://academic.oup.com/carcin/article-abstract/28/3/625/2476293
by Belgrade University user
on 15 March 2018
cancer incidence. No major differences were found between incidence/
mortality rates in the study cohorts and the national reference rates. Twenty-
one subjects diagnosed with a non-melanoma skin cancer (ICD-IX 173) were
excluded from the analyses.
In order to standardize for the marked inter-laboratory variability (see
Table I) MN frequency was categorized by tertiles of the laboratory-specific
distributions, i.e. 33%, 34–66%, >66%, and subjects were classified as
having low, medium or high MN frequency, respectively. Information about
occupational exposure to mutagens or carcinogens was collected as reported
in the original studies, and re-classified according to the job-exposure matrix
described by the ESCH group (17). Data on smoking status at the moment of
cytogenetic testing were available in all cohorts, and subjects were classified
as current, former or never smoker without consideration of the level of
smoking. MN frequency was significantly increased in those subjects who
were occupationally exposed to mutagens and carcinogens when compared
with unexposed controls (P < 0.005), and to a lesser extent in heavy smokers
when compared with those who never smoked (P < 0.044).
Statistical methods
Regression models were fitted to the data assuming that cancer incidence
rates follow the negative binomial distribution (NB) (23). This distribution in
presence of overdispersion, a phenomenon that frequently arises with count
data, provides more efficient estimates of the standard errors of the models
parameters. The NB variance function is
VðmÞ ¼ mþ jm2
where m is the NB mean and j is the overdispersion parameter. NB reduces
to the Poisson distribution when this parameter tends to zero.
The effect of MN frequency on cancer incidence was evaluated by com-
paring cancer incidence rates for the medium and high levels versus the
low level, after adjusting for the confounding effects of age, gender, smoking
status and occupational exposure to mutagens or carcinogens. A random
effect term was then included in the models to adjust for the differences
in cancer rates occurring among countries. The presence of effect modifi-
cation was tested by computing the log-likelihood ratio test for two hier-
archical models, the first with, and the second without interaction terms
involving MN.
To verify if the presence of pre-clinical stages of cancer might have
influenced MN frequency at test we repeated the analyses excluding the first
2 years of follow-up. Furthermore, we stratified the entire cohort according
to the median follow-up time among the cancer cases, i.e. <6 and 6 years,
and tested for the presence of effect modification due to time since test.
Given the homogeneous pattern of cancer incidence and cancer-free
survival in the medium and high tertiles, the analyses by country and cancer
site, which generally had a number of events too low to allow the analysis on
three strata levels, were performed combining these two tertiles. These
additional analyses were performed in groups with at least 10 observed cases.
The effect of MN frequency on the probability to be cancer free at the end
of the follow-up was estimated by means of Cox’s proportional hazard model
(24), using time since test as the time variable and adjusting for age, gender,
smoking status and occupational exposure. STATA software was used for all
statistical analyses (25).
Results
An overall number of 219 incident cancers (including 7 cases
from Italy) and 56 cancer deaths were registered at the end of
the follow-up periods. The most frequent cancer sites were
colon and rectum (37), stomach (35), lung (28) and breast
(20), mostly contributed by Japan, Italy and Sweden where
the person-years were the largest and the mean ages of the
cohorts were the highest.
The association between overall cancer incidence and
MN frequency is described in Table II. Significant increases
were found for subjects in the medium group(Relative Risk
(RR) ¼ 1.84; 95% confidence interval (CI) 1.28–2.66) and
high tertiles (RR ¼ 1.53; 95% CI 1.04–2.25), when compared
with the low tertile. Removing the first 2 years of follow-up
(which most likely are affected by undiagnosed cancers)
Table I. Selected characteristics of the study population
Country Labs (N) Subjects Cancer
cases
Person-years Year(s)
of test
(min–max)
Median
follow-up
(years)
MN frequency
[mean (SD)]
Age
[years
mean (SD)]
Males (%) Exposed (%)a Current
smokers (%)
Belgiumb 1 146 0 599 1991–1996 4.0 3.9 (2.3) 40.3 (9.3) 100.0 50.0 45.9
Bulgaria 1 208 4 1264 1993–1996 6.3 41.1 (28.6) 47.5 (8.5) 63.0 67.3 57.7
Croatia 1 202 4 1841 1988–1999 9.5 59.0 (41.5) 46.5 (9.9) 71.3 100.0 53.0
Italyb,c 7 2654 56 25476 1984–1999 9.3 4.6 (4.2) 54.9 (15.3) 57.9 19.6 29.3
Japan 1 833 146 7935 1988–1990 10.6 52.2 (14.6) 72.3 (9.6) 40.8 100.0 26.6
Poland 1 205 11 1839 1989–1998 11.5 14.3 (10.0) 50.8 (11.4) 100.0 44.4 60.0
Slovakia 4 923 10 7735 1993–1998 8.0 12.1 (6.1) 46.1 (9.6) 39.1 72.6 38.3
Sweden 2 677 31 10440 1980–1986 15.8 4.1 (2.7) 54.9 (11.4) 87.7 59.0 40.3
Taiwan 1 194 2 1443 1983–1996 7.7 13.3 (11.1) 42.2 (10.6) 33.5 52.1 21.5
Yugoslavia 1 676 4 4408 1988–2002 5.6 11.6 (9.3) 44.3 (9.0) 53.7 69.2 41.1
Total 20 6718 268 62980 1980–2002 8.5 15.5 (21.0) 53.7 (15.0) 57.7 52.2 35.2
aExposure to known or potential carcinogens at the time of blood sampling.
bMortality follow-up.
cIncidence data were also available for 245 subjects out of 2654 (7 cancer cases; 1459 person-years)
Table II. Relative risk of cancer incidence by MN frequency, gender,
occupational exposure to carcinogens and smoking status
Covariate Cases Subjects Person-years RRa 95% CI P-value
MN frequency
Low* 51 1307 12 415 1 —
Medium 91 1426 13 014 1.84# 1.28–2.66 0.001
High 77 1430 12 935 1.53# 1.04–2.25 0.03
Gender
Female* 86 1814 15 062 1 —
Male 133 2349 23 302 1.46 1.02–2.10 0.04
Occupational exposureb
No 25 1169 10 813 1 —
Yes 194 2953 27 274 1.41 0.85–2.35 0.19
Smoking statusc
Never 94 2272 20 849 1 —
Former 30 247 2246 1.23 0.76–2.01 0.40
Current 85 1575 14 786 1.49 1.06–2.11 0.02
RR estimated by negative binomial regression analysis (4163 subjects).
All cancers: ICD IX 140–208.
aRR, relative risk adjusted also by age (5 years unit), country, time since
MN test; CI, confidence interval.
b41 subjects with missing data.
c69 subjects with missing data.Reference group.
#Corresponding unadjusted RR (95% CI) for medium and high tertiles are
1.67 (1.20–2.34) and 1.47 (1.04–2.07), respectively.
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from the statistical analysis, did not change the risk estimates
(13 cancer cases occurred within this time frame). Similarly,
after splitting the follow-up period into two equal time
periods, no differences were observed between RR’s for
medium and high levels of MN in the period immediately
after the MN assay (<6 years) and in the period thereafter
(6 years). The limited impact of confounding due to
variables that affected MN frequency (i.e. age, gender,
occupational exposure to genotoxins and smoking status)
is shown by the small differences between the adjusted
and unadjusted relative risks, i.e. 1.84 (1.28–2.66) versus
1.67 (1.20–2.34) for medium tertile and 1.53 (1.04–2.25)
versus 1.47 (1.04–2.07) for the high tertile, respectively.
However, after stratifying by gender, females showed a linear
trend of RRs by MN frequency level, i.e. 1.00; 1.51; 1.96, for
low, medium and high, respectively (test for linear trend,
P < 0.03). Occupational exposure to mutagens or smoking
status did not significantly modify the relationship between
MN frequency and cancer risk.
The association between cancer risk and MN level is con-
sistent over the follow-up time, as clearly shown by Figure 2,
which indicated a significantly worse outcome in subjects
in the medium and high MN tertiles (P ¼ 0.001 and 0.025,
respectively).
The MN frequency in the medium/high tertiles also
presaged an increased risk of cancer within national cohorts,
as reported in Table III. Only findings from Japan, which is
the oldest national cohort and has the largest number of
events, reached statistical significance, i.e. RR ¼ 1.53 (1.06–
2.21). However, a significant association (RR ¼ 2.54; 1.19–
5.40) between MN frequency and cancer risk was found
when incidence data from all other countries (excluding
Japan) were pooled.
The risks associated with specific cancer sites was tested
after combining the medium/high tertiles and selecting those
sites with a high number of cases (Table IV). All cancer sites
evaluated—except for cancer of liver, biliary ducts and
pancreas (RR ¼ 0.63; 0.27–1.44)—showed a higher RR in
the medium/high MN tertile. A significantly increased risk
was found only for the group of urogenital cancers (ICD-IX
179–189), RR ¼2 .83; 1.19–6.74), with the highest RR being
for bladder and kidney cancers (n ¼ 16; RR ¼ 8.23; 1.08–
63.0). A significant association was also found by combining
gastro-intestinal cancers (ICD-IX 151–154), RR ¼ 1.74;
Fig. 2. Probability curves of cancer free survival by tertile of MN frequency (pooled data from the HUMN cohort). Cancer free survival refers to time from
MN test to the first cancer diagnosis. The association between MN and survival was estimated using the multivariate Cox proportional hazard model.
(all cancer incidence ICD IX 140–208).
Table III. Relative risk of cancer incidence by MN frequency and country
Country MN
tertiles
Cases Subjects Person-years RRa 95%
CI
P-value
Italyb Low 12 812 7803 1 —
Medium/high 44 1842 17 673 1.37 (0.72–2.62) 0.34
Japan Low 42 274 2690 1 —
Medium/high 104 559 5245 1.53 (1.06–2.21) 0.02
Sweden Low 4 201 3287 1 —
Medium/high 27 476 7153 2.24 (0.77–6.52) 0.14
Other countries Low 4 754 5960 1 —
Medium/high 31 1654 12 570 2.85 (0.99–8.23) 0.053
RR estimated by negative binomial regression analysis (4163 subjects). All cancers: ICD IX 140–208.
aRRs adjusted by sex, age (5 years unit), time since MN test, exposure to carcinogens and smoking status at test.
bMortality data.Reference group.
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1.01–4.71. No statistics could be provided for breast cancer
because none of the 14 incident cases fell in the reference
tertile (7 in the medium and 7 in the high, respectively).
Discussion
The results from the present study support the hypothesis that
MN frequency in PBL is a predictive biomarker of cancer
risk. These data strengthen and extend the evidence
accumulated by experimental, mechanistic and association
studies (1), that the extent of genetic damage measured in
lymphocytes reflects the occurrence of early carcinogenic
events in the target tissues. The strengths of this study
include the relatively large size of the study group, the same
direction of risk estimates in all countries, and the
independence of results from the time elapsed between MN
testing and cancer diagnosis. However there are some
limitations, which are discussed below.
A specific association was found in a number of cancer
sites, although statistical significance was reached only in the
groups of urogenital and gastro-intestinal cancers. In
particular, the higher risks for stomach (1.63) and intestinal
cancers (1.75), (RR ¼ 1.74; 1.01–4.71, when combined), are
in agreement with the literature, which emphasizes the role of
chromosome rearrangements in the early stages of these
tumours (26–28). Further, a strong association between CA
frequency in PBL and the risk of stomach cancer (n ¼ 12;
RR ¼ 7.79; 1.01–60.0) has been described in a recent cohort
study performed in the Czech republic (19), and in a new
independent cohort of five Central and Eastern European
countries (RR could not be evaluated because none of 15
cases of stomach cancer fell in the reference tertile, but the
test for linear trend was highly significant; P < 0.01) (29).
The lack of breast cancer cases in the low MN tertile relative
to 14 breast cancer cases in the mid/high tertiles suggests that
elevated MN may be related prospectively with breast cancer
risk for which there is evidence of an association in case–
control studies (30). Nevertheless, we acknowledge that the
number of cancers per organ site is relatively small, and that
the statistical estimates, which are suggestive of an associa-
tion with MN, are likely to become more stable as further
cancers accumulate with increasing age of the cohort.
A feature of this study is the non-linearity of the dose–
response relationship between MN frequency and overall
cancer incidence, showing that subjects in the medium and
high tertile have a higher risk of cancer relative to the low
tertile, but there was no significant difference between
medium and high tertiles. A non-linear relationship between
MN frequency and the risk of cancer seems the most likely
explanation, assuming that there is a value of MN frequency
beyond which no further increase in cancer risk occurs, e.g.
cells with excessive genome damage may be eliminated by
apoptosis. Alternative explanations include selective loss of
genetic material, i.e. subjects with high frequency of MN
might more easily lose chromosomes not often involved in
carcinogenesis (such as sex chromosomes), or the role of
nuclear budding, a mechanism to eliminate excess amplified
DNA or chromosomes (4,31–34). Furthermore, genome
damage-induced cell death has been found in many other
diseases, such as neurodegenerative disease (35), which
could also explain the plateau effect given that association
with other degenerative disease was not explored. The
presence of a linear trend of RRs in the subgroup of
women, who were much less occupationally exposed relative
to males (data not shown), suggests that the observed non-
linearity may have, to some extent, been caused by
incomplete adjustment for occupational exposure.
While a residual confounding due to occupational expo-
sure to mutagens or smoking status is still possible (as shown
by the small difference between adjusted and unadjusted
relative risk estimates), statistical analysis showed a lack of
effect modification, i.e. the risk associated with MN
frequency is the same in exposed and unexposed, as well as
in smokers and non-smokers. Similar results were described
in a case–control study nested within the ESCH cohort study
on CA (17). In that study the authors concluded that CA is a
predictor of cancer risk which is independent from exposure
to mutagen/carcinogenic agents (occupational exposure and
smoking habit was re-assessed by an international group of
occupational hygienists). The similarity of our findings seems
to support the same conclusion in the present cohort study,
but the limitation in the exposure assessment (original data as
reported by authors were used on a yes–no basis) has limited
the possibility of further evaluation of carcinogen/mutagen
exposure effects.
Formation of nuclear anomalies such as MN, chromosomal
rearrangements and anaphase bridges (leading to breakage-
fusion-bridge cycles and generation of more MN) are events
commonly seen in the early stages of carcinogenesis
(4,26,36). Elevated levels of MN are indicative of defects
in DNA repair and chromosome segregation which could
Table IV. Relative risk of cancer incidence and mortality by MN frequency and cancer site
Tumour site (ICD IX) MN tertile Cases RRa 95% CI P-value
Liver, biliary ducts and
pancreas (155–157)
Low 14 1 —
Medium/high 15 0.63 (0.27– 1.44) 0.27
Lung (162) Low 7 1 —
Medium/high 21 1.54 (0.63–3.77) 0.35
Stomach (151) Low 8 1 —
Medium/high 27 1.63 (0.70–3.82) 0.26
Colon-rectum (153–154) Low 10 1 —
Medium/high 27 1.75 (0.84–3.66) 0.14
Urogenital (179–189) Low 6 1 —
Medium/high 36 2.83 (1.19–6.74) 0.002
RR estimated by negative binomial regression analysis.
aRRs adjusted by gender, age (5 years unit), time since MN test, exposure to carcinogens and smoking status at test.Reference group.
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result in generation of daughter cells with altered gene
dosage, or deregulation of gene expression that could lead to
the evolution of the chromosome instability phenotype often
seen in cancer (1,2,9,10,13,37). These considerations give
mechanistic support to a possible causal association between
MN frequency and the risk of cancer. The observed
association between MN frequency and cancer risk in non-
haematological malignancies in our study suggests that
genome damage events in lymphocytes may be correlated
with cancer initiating events in other tissues via a common
genetic, dietary or environmental factor. This is also
supported by a recent paper indicating that specific chromo-
somal rearrangements play a role not only in haematological
malignancies but also in non-haematological malignancies,
and that there may be no fundamental tissue-specific
differences in the genetic mechanisms by which neoplasia
is initiated (38).
A major challenge in the mechanistic interpretation of our
findings is the fact that MN can be generated through
different processes, i.e. chromosome breakage and chromo-
some loss (aneuploidy), occurring roughly in the same
proportion (1). In contrast to chromosome breakage, whose
role in early stages of carcinogenesis has extensively been
studied, the significance of aneuploidy is still poorly
understood, although it is well known that aneuploidy is a
hallmark of the majority of human tumours, and is associated
with high grade invasiveness and poor prognosis (39).
Studies of the cytogenetic evolution in breast cancer have
suggested that a highly aneuploid state could originate from a
polyploidization event concurrent with a gradual loss of
individual chromosome copies (40). Similar findings have
also been reported for preneoplastic lesions of the colon (41),
oesophagus (42) and cervix (43). Cancer risk estimates
associated with MN frequencies in the present study are
roughly similar to the estimates reported for CA. Our
findings confirm the predictive role of chromosome anomal-
ies but they do not provide definitive evidence concerning the
role of aneuploidy. A resolution of this issue may result from
future studies designed to distinguish between these mecha-
nisms using centromere and telomere detection in MN, and
including measurement of nucleoplasmic bridges which are
a marker of misrepair of DNA lesions and telomere end-
fusion (9,28,44).
The international multi-centre nature of this study may be
considered among its strengths because this design allowed
us to explore various environmental exposures in diverse
genetic backgrounds (using the country as a proxy of genetic
features). On the other hand, this approach has also
introduced a number of limitations. These include the large
inter-laboratory variability of MN frequency which is most
likely due to technical differences in slide preparation and
scoring, the heterogeneous quality of data on genotoxic
exposures such as cigarette smoking and occupational
carcinogens or the availability of a single measure of MN
per individual which may have resulted in misclassification
among MN frequency levels. A further potential source of
bias is the heterogeneity in the cancer registration quality
in the countries involved. All these potential sources of
discrepancy—including the intrinsic limitation due to mea-
surement of MN in a surrogate tissue—may have weakened
the observed association between MN and cancer incidence.
In addition, the young age of the cohort (mean ¼ 53.7 years)
limited the number of cancer cases, i.e. 4% of the whole
study group, contributing to a reduced stability of risk
estimates. The uneven contribution of national cohorts to the
main database, and the much larger contribution of cancer
cases from Japan, may have added some uncertainty to the
random effects model and made the statistical estimates less
stable. However, despite the uneven size of the cohorts, the
increased RR’s in all national cohorts, as shown in Table III,
adds confidence to the reliability of the statistical model used
for the overall analysis.
Additional research is needed not only to have a better
insight into the association between the MN frequency and
cancer, but also to evaluate the benefits of including
biomarkers of cancer risk in the surveillance of populations
at increased environmental or genetic risk. The first goal is
easier to achieve, and plans already exist within the
framework of the HUMN project for increasing the size of
the study group, by both including new national cohorts and
extending the length of the follow-up period for those cohorts
currently included in the study. The second goal is more
complex given the relatively low risk predicted by MN
frequency and the limited evidence of specific association
with cancer site or genotoxic agent. A better understanding
of this association, especially taking into account the role
of possible confounders and effect modifiers such as diet,
oxidative stress and genetic polymorphisms, would be
desirable before routine application of these biomarkers in
population studies to estimate the risk of cancer.
Although the prospect of reducing chromosome damage
and MN frequency by dietary, life-style and occupational
changes may appear feasible (8,11,44), it will also be
desirable and necessary to measure the actual impact of
MN frequency reduction on cancer incidence prospectively.
In conclusion, this study provides preliminary evidence
that MN frequency in PBL is predictive of cancer risk,
suggesting that increased MN formation is associated with
early events in carcinogenesis. However, it is important to
emphasize that the findings of this study pertain to the risk of
a group and not individuals. The wide-spread use of the MN
assay in the monitoring of environmental and occupational
exposure to genotoxins, its responsiveness to the effects of
micronutrients and diet and its ability to identify high-risk
groups of susceptible individuals, provides a further possi-
bility for the use of the MN assay in the planning,
implementation and validation of cancer surveillance and
prevention policies.
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